Purpose of review Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, for which treatment guidelines are still evolving. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapeutic modality for ALL, and this review describes the recent studies and current practice patterns concerning the who, when, and how of allo-HCT in the management of ALL.
INTRODUCTION
Approximately 5000 patients annually are diagnosed with acute lymphoblastic leukemia (ALL), of which about 1400 will die [1] . Despite high induction remission rates for ALL (80-90%), the overall survival (OS) rate is low in the adult population (30-40%) [2] . Over the last few years, a variety of factors have contributed to prolongation of survival in adult ALL: improved outcomes with allogeneic hematopoietic cell transplantation (allo-HCT), addition of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive ALL, and increased use of intensified pediatric-like chemotherapy protocols for adolescent and young adult populations. This article will focus on the role of allo-HCT in the treatment of adult ALL.
WHICH PATIENTS SHOULD BE TRANSPLANTED?
Philadelphia chromosome positive BCR-ABL acute lymphoblastic leukemia
The incidence of Philadelphia chromosome positivity (Ph þ ) in ALL is 15-30% with some evidence that incidence increases with age, reaching up to 50% in elderly patients [11] [12] [13] [14] . The prognosis of Ph þ ALL is poor, especially in older populations, and allo-HCT remains the only potential curative option [15] . In the French LALA94 trial, the estimated 3-year OS for patients who had donors and achieved CR1 was 37 versus 12% for other patients (P ¼ 0.02) [16] . The benefit of allo-HCT has also been observed in longterm follow-up of patients receiving allo-HCT in CR1 at City of Hope (COH) and Stanford University, with a 10-year OS of 54% [17] . Since the introduction of imatinib, a TKI, for treatment of BCR-ABL malignancies, there has been interest in combining TKIs with induction chemotherapy and/or HCT in patients with Ph þ ALL. Imatinib has been studied both as a single agent and incorporated within induction chemotherapy regimens for newly diagnosed Ph þ ALL, demonstrating high response rates, improved survival in combination settings, and feasibility and tolerability in older populations [18] [19] [20] [21] [22] . TKIs such as imatinib, dasatinib, and nilotinib are now standard therapy for Ph þ patients and the resultant increase in initial remission rates has allowed greater eligibility for allo-HCT. A recent study by Mizuta et al. [23] compared 51 patients who received imatinib in combination with chemotherapy followed by allo-HCT in CR1, with 122 patients who received allo-HCT in CR1 during the preimatinib era. The 3-year OS of the imatinib group was 65% compared to 44% for the preimatinib group. Patients with BCR-ABL transcript positivity after allo-HCT seem to experience higher relapse rates compared to BCR-ABL-negative patients (45 versus 23%, P ¼ 0.0013) [24] . This phenomenon led to early initiation of posttransplant TKI therapy, when leukemic cell burden is minimal; some suggest beginning at 90 days after transplant [25, 26] . The optimal duration of TKI therapy after allo-HCT has not yet been determined, but some physicians continue using TKI as long as patients tolerate it. In a recent study, the median duration of imatinib therapy after allo-HCT was approximately 1 year (range, 3-50 months) [27] .
Relapsed and refractory patients
Patients with ALL refractory to primary chemotherapy or who relapse have extremely poor prognoses; allo-HCT is the only curative option if they can achieve remission pretransplantation. According to the LALA94 study, OS at 5 years is only 9% for relapsed patients after allo-HCT; however, for the patients who had available donors and were able to achieve a second complete remission and survive until allo-HCT (61/421), 5-year OS was 33% [28] . Likewise, outcomes from 609 patients on the MRC/ECOG 2993 study showed a 23% 5-year OS for patients receiving a sibling allo-HCT (n ¼ 42), whereas patients receiving matched unrelated donor allo-HCT (n ¼ 65) had a 5-year OS of 16%, compared to 15% for autologous hematopoietic cell transplantation (auto-HCT) and 4% for chemotherapy [29] . Marks et al. [30 & ] recently demonstrated that the relative risk of relapse is significantly higher for patients with Ph þ ALL in CR2 compared to CR1, particularly for those patients whose duration of CR1 was less than 1 year. Outcomes for patients with active disease are dismal and this contributes to the argument that perhaps all patients should be transplanted in CR1, as CR2 is frequently not achievable.
Patients with minimal residual disease
In addition to age and cytogenetics at diagnosis, the most important prognostic factor, and a direct
KEY POINTS
Allogeneic hematopoietic cell transplantation remains a potential curative therapy for patients with high-risk features and patients with relapsed disease.
On the basis of MRC/ECOG data, it is worth considering allogeneic transplant for standard-risk patients, as the relapse rate is high and the prospects of achieving CR2 are uncertain.
The importance of minimal residual disease (MRD) monitoring is evolving as a prognostic factor and an indication for allogeneic transplant.
Peritransplant use of tyrosine kinase inhibitors might improve the outcome in adult patients with Ph þ ALL.
Recent advances in transplant, including feasibility of reduced-intensity conditioning for ALL, and alternative stem cell sources have improved outcomes and made transplant accessible to a wider range of patients.
reflection of sensitivity to chemotherapy, is the achievement of complete remission. Assessing disease status postinduction by morphological examination of the bone marrow is limited because of the similarity between malignant lymphoblasts and B-lymphocyte progenitors. More accurate and sensitive quantification of malignant cell persistence postinduction can prevent undertreatment of patients with residual disease and overtreatment of disease-free patients [31] . Studies in pediatric ALL populations demonstrate an association between adverse outcomes and persistence of MRD [32] [33] [34] [35] [36] [37] . The role of MRD quantitation to evaluate treatment response and predict relapse is evolving in adult populations, with exploration of flow cytometry and real-time quantitative polymerase-chainreaction techniques. Presence of MRD is associated with adverse outcomes even in patients otherwise considered at standard risk and these patients may benefit from early allo-HCT in CR1 [31, 35, [38] [39] [40] [41] .
The question is at what MRD level do we consider the patient at risk of disease relapse? Stow et al. [42] find that pediatric patients with MRD of at least 0.001% (one malignant cell per 100 000 cells) have a significantly higher 5-year cumulative risk of relapse (12.7 AE 5.1%), compared to patients with less than 0.001% (5.0 AE 1.5%), with P < 0.047. The authors point out that even 0.001% represents an estimated total leukemic burden of 10 7 to 10 8 malignant cells. Until further investigation, an MRD level of 10 -4 (0.01%) or greater is the current determinant of high risk for disease relapse [43] [44] [45] .
WHEN SHOULD TRANSPLANT BE PERFORMED?
Should a patient receive a high-risk classification, there is generalized agreement to proceed to allo-HCT. There is a dilemma when a patient has standard risk for relapse; should we transplant in CR1 or wait until they have relapsed? In the future, MRD will play a greater role in this decision, but most previous studies on this issue do not take MRD into account.
Transplant in CR1 for high-risk patients
Early randomized trials that compared allo-HCT to chemotherapy or auto-HCT have relied on a genetic randomization based on the availability of an HLAmatched sibling. The French multicenter randomized trial, LALA-87, found that only patients with high-risk features (Ph þ ALL, WBC >30 x 10 9 , undifferentiated ALL, age >35 years, or time to CR1 >4 weeks) have better OS (P ¼ 0.03) and disease-free survival (DFS) (P ¼ 0.01) with allo-HCT, whereas patients with standard risk showed no significant advantage of allo-HCT over chemotherapy or auto-HCT [46] . This was confirmed in a larger study from the same group, LALA-94, which additionally concluded that there is no significant difference in DFS between auto-HCT and chemotherapy for high-risk patients [47] as detailed in Table 2 . Several other reports indicate that allo-HCT offers some groups of high-risk patients in CR1, long-term survival rates of between 40 and 60% [48] [49] [50] [51] . COH and Stanford University updated two series of patients with high-risk features who underwent allogeneic HCT in CR1 with a median follow-up of greater than 5 years. Selection criteria included white blood cell (WBC) count greater than 25 000/ml; chromosomal translocations t(9;22), t(4;11), t(8;14); age older than 30 years; extramedullary disease at the time of diagnosis; and/or requiring greater than 4 weeks to achieve CR1. Allo-HCT during CR1 in this patient population, who would otherwise have been expected to fare poorly, led to an event-free survival (EFS) of 64% with a relapse rate of 15% [52] .
Transplant in CR1 for standard-risk patients?
The recently reported MRC/EGOG trial compared allo-HCT, auto-HCT and chemotherapy alone in ALL patients in CR1. ALL Ph þ patients with either a related or unrelated donor proceeded to allo-HCT, but standard-risk and high-risk patients underwent a sibling donor versus no-sibling donor biological allocation to allo-HCT. Patients without donors were then randomized to auto-HCT or chemotherapy. Allo-HCT resulted in improved disease control in all adult patients with ALL, but with long-term benefit seen most significantly in younger patients with lower risk disease (Table 3) [53, 54] . Considering the previously reported data indicating benefit from transplant in high-risk patients in CR1, and the high treatment-related mortality from allo-HCT, this trial has led to considerable debate about the implications for patients with ALL; some experts advocate early transplant for nearly all patients, whereas others caution for continued individual assessment.
WHICH TRANSPLANT REGIMEN?
Traditionally, high-intensity preparative regimens are used for ALL, but more recently, there have been multiple observations pointing to a graft-versusleukemia (GVL) effect that have led to the introduction of less toxic regimens, making transplant more feasible for patients who otherwise would not be candidates.
Myeloablative regimens
The ideal preparative regimen for allo-HCT in ALL should maximize antileukemic effects, while maintaining efficient engraftment and tolerable toxicity. Total body irradiation (TBI)-based regimens have been the mainstay of ALL preparative regimens because of their ability to eradicate leukemic cells within the central nervous system and testicles, providing prolonged EFS and lower relapse rates [55] [56] [57] . TBI in combination with cyclophosphamide (TBI/ Cy) is the most common ALL transplant preparative regimen. Because of radiation toxicities including secondary malignancies, cataracts, and interstitial pneumonitis, other preparative regimens have been explored. Busulfan/cyclophosphamide (Bu/Cy) conditioning shows comparable OS, relapse rate, and DFS to the TBI/Cy regimen; however, it is also associated with serious side-effects, including hepatic sinusoidal obstruction syndrome (SOS) -previously venoocclusive disease, VOD -and hemorrhagic cystitis [58] [59] [60] . Conversion from oral to intravenous busulfan in the Bu/Cy regimen has decreased incidence of SOS and improved 100-day survival [61] . More recently intravenous Bu/Cy in CR1 patients produces 30-month OS and relapse rates of 65.7 and 40% with decreased transplant-related mortality (TRM) and SOS [62] .
COH substituted etoposide (VP16) for cyclophosphamide in combination with fractionated TBI (13.2 Gy) followed by allo-HCT for ALL [63] . DFS was 57% with a 32% relapse rate, suggesting the regimen has significant activity in patients with advanced ALL. This result was confirmed in a subsequent trial by the Southwest Oncology Group comparing TBI/VP16 with Bu/Cy [64] . A comparative analysis of TBI combined with either cyclophosphamide or etoposide chemotherapy [65] concluded there is an advantage in substituting etoposide for CY or, when CY is used, in increasing the TBI dose to greater than 13 Gy.
The role of the graft versus leukemia effect and reduced intensity conditioning
Although the primary therapeutic effect of allo-HCT in ALL is believed to result from eradication of the leukemic cells using high-dose therapy, there is also evidence of a GVL effect. Observations of higher relapse rates after autologous or syngeneic HCT compared with allo-HCT, lower incidence of relapse in patients with graft versus host disease (GVHD), and increased relapse rates in recipients of T-celldepleted marrow grafts, all point to GVL [66] . A recent report from Fred Hutchinson Cancer Research Center indicates that early withdrawal of immunosuppressive therapy in patients who do not develop GVHD decreases the risk of disease relapse in the first 18 months after transplant [67] . The general consensus that the intensity of myeloablative conditioning is important for disease control after allo-HCT has limited its availability to patients with advanced age or comorbidities. Results of the MRC/EGOG study revealed significant TRM for ALL allo-HCT patients over age 35 compared to consolidation chemotherapy, resulting in no improvement in DFS despite better disease control. This and similar data stimulated investigations of reduced intensity conditioning (RIC) therapy [68, 69] . A retrospective analysis of high-risk ALL patients receiving allo-HCT demonstrates a promising 2-year OS/DFS of 61%, relapse rate of 21%, and nonrelapse mortality (NRM) of 21.5% [70] . An EBMT retrospective study compares RIC with conventional myeloablative conditioning, finding a higher relapse rate with RIC (P ¼ 0.03, hazard ratio ¼ 0.59), but a correspondingly decreased NRM (P ¼ 0.0001, hazard ratio ¼ 1.98) [71] . More recently, a prospective study of 51 patients with high-risk ALL reveals a 3-year relapse rate of 40% with 28% NRM. The 3-year OS for patients in CR1 are 52% for CR1, 62% for CR1 Ph þ (received imatinib after engraftment), and 73% for patients with no evidence of MRD [27] . These studies contradict the dogma that RIC is inadequate to affect cure in ALL and indicate that it is a reasonable choice for patients with advanced age or comorbidities.
WHICH DONOR CELL SOURCE?
Matched related donors have been the ideal choice for ALL transplant, because of lower incidence and severity of GVHD. Advances in HLA typing technology, alternative donor sources, and GVHD prophylaxis have opened up new stem cell sources for patients without available matched related donors.
Unrelated donors versus related donors
Outcomes after transplantation from unrelated donors were previously inferior to those observed after matched-sibling transplantation because of increased rates of graft rejection and GVHD. Improvements in donor/recipient allele-level molecular matching in class I and II histocompatibility genes, GVHD prophylaxis, and supportive care [72] High risk is defined as age of at least 35 years, WBC greater than 30 000/ml for patients with B-cell disease or WBC greater than100 000/ml for patients with T-cell disease, or time to attain complete remission greater than 4 weeks.
have made donor allografts safer. Recently, a retrospective analysis in 221 patients reported 5-year DFS after allo-HCT in CR1 from matched unrelated donors of 45%, compared to 42% in patients with matched related donors [73] . More recently, a study of 1139 patients revealed the 4-year OS for allo-HCT in CR1 was not different between related versus unrelated donors at 65 versus 62%, respectively (P ¼ 0.19) [74] . These data suggest that unrelated donors are a reasonable option for patients with ALL who do not have an available related donor.
Haploidentical donors/umbilical cord donors
One major obstacle to initiation of transplant is the timely availability of a donor. Recent reports in pediatric populations indicate that allo-HCT from haploidentical donors [75] or from cord blood [76] is 
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feasible and can provide promising alternatives for patients who lack HLA-matched donors. In the adult population, the data are still evolving, but early reports suggest the feasibility of such approaches [77, 78] . Further development of alternative cell sources needs to be carefully evaluated in a prospective fashion.
TREATMENT STRATEGY FOR ACUTE LYMPHOBLASTIC LEUKEMIA
ALL is a heterogeneous disease and management should be tailored for each patient. The National Comprehensive Cancer Network is in the process of developing a general practice guideline for ALL; until then, our suggested treatment strategy is outlined in Fig. 1 .
CONCLUSION
There are multiple ALL trials in process to test immunotherapeutic modalities such as incorporation of targeted CD52 or CD22 monoclonal antibodies with chemotherapy or bi-specific T-cell engagers (BiTEs). ,80]. Currently, an investigational new drug application and clinical protocol are under development at COH to explore adoptive T-cell therapy using a similar CD19 adoptive T-cell therapy for B-cell ALL. In addition to the development of novel therapeutic agents, a crucial area of research will be refinement of MRD monitoring to improve patient selection and timing for allo-HCT. Future prospects for adults with ALL are hopeful, as we expand our understanding of the disease and incorporate multiple treatment modalities, including allo-HCT.
